Controversial FDA Official Behind Aduhelm Approval Departs FDA

Billy Dunn, director of the FDA’s Office of Neuroscience (ON) and a key figure in the FDA’s controversial June 2021 approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab), is officially leaving the agency after nearly two decades.
Source: Drug Industry Daily